Kodiak

About us

Kodiak Sciences is a biopharmaceutical company based in Palo Alto, California, founded in 2009. The company specializes in developing therapies for retinal diseases, focusing on ophthalmology. Kodiak aims to prevent and treat major causes of blindness, such as age-related macular degeneration and diabetic retinopathy. The company's innovative Antibody Biopolymer Conjugate Drug (ABCD) Platform enables the treatment of complex ocular and systemic diseases. Kodiak has a late-phase pipeline that includes key programs like Tarcocimab, an anti-VEGF therapy for retinal vascular diseases, and KSI-101, which is in Phase 3 development for macular edema secondary to inflammation. Kodiak is dedicated to advancing retinal medicine and aims to be a leader in the field by attracting top talent and technologies.

More information